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Abstract 
Background: Hypertension remains a public health challenge worldwide. In the Democratic Republic of Congo, its 
prevalence has increased in the past three decades. Higher prevalence of poor blood pressure control and an increas-
ing number of reported cases of complications due to hypertension have also been observed. It is well established 
that non-adherence to antihypertensive medication contributes to poor control of blood pressure. The aim of this 
study is to measure non-adherence to antihypertensive medication and to identify its predictors.
Methods: A cross-sectional study was conducted at Kinshasa Primary Health-care network facilities from October 
to November 2013. A total of 395 hypertensive patients were included in the study. A structured interview was used 
to collect data. Adherence to medication was assessed using the Morisky Medication Scale. Covariates were defined 
according to the framework of the World Health Organization. Logistic regression was used to identify predictors of 
non-adherence.
Results: A total of 395 patients participated in this study. The prevalence of non-adherence to antihypertensive 
medication and blood pressure control was 54.2 % (95 % CI 47.3–61.8) and 15.6 % (95 % CI 12.1–20.0), respectively. 
Poor knowledge of complications of hypertension (OR = 2.4; 95 % CI 1.4–4.4), unavailability of antihypertensive drugs 
in the healthcare facilities (OR = 2.8; 95 % CI 1.4–5.5), lack of hypertensive patients education in the healthcare facili-
ties (OR = 1.7; 95 % CI 1.1–2.7), prior experience of medication side effects (OR = 2.2; 95 % CI 1.4–3.3), uncontrolled 
blood pressure (OR = 2.0; 95 % CI 1.1–3.9), and taking non-prescribed medications (OR = 2.2; 95 % CI 1.2–3.8) were 
associated with non-adherence to antihypertensive medication.
Conclusion: This study identified predictors of non-adherence to antihypertensive medication. All predictors identi-
fied were modifiable. Interventional studies targeting these predictors for improving adherence are needed.
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Background
Hypertension (HTN) remains a public health challenge 
worldwide because of its high prevalence and related 
complications. In 2000, 26.4  % of the World’s adult 
population had hypertension [1]. In Sub-Saharan Africa 
(SSA), the prevalence of HTN varied from 6 to 48 % [2]. 
In the Democratic Republic of Congo (DRC), the preva-
lence of HTN has been increasing for the past three dec-
ades. In 1987, the prevalence was 14.2  % in urban and 
9.9  % in rural areas [3] and almost doubled in 2005 to 
reach 26.7 % [4].
In SSA, the control of HTN is low. For example, in 
West African countries this control is low, less than 10 % 
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except for Nigeria where it is approximately 30 % [5]. In 
the DRC, the Vitaraa study conducted in Southern Kivu 
found that 86.4  % of hypertensive patients were uncon-
trolled [6]. Uncontrolled HTN is one of the main cardio-
vascular risk factors (CVRF) [7] and based on the World 
Health Organization (WHO) estimates, at least 50  % of 
cardiovascular diseases (CVD) and 75  % of strokes are 
consequences of high blood pressure [8]. In the DRC, 
HTN-related complications including stroke, chronic 
kidney disease (CKD) are increasingly reported [9–11].
Non-adherence to antihypertensive medication (NAM) 
is one of the main factors contributing to uncontrolled 
HTN [12]. In fact, benefits of antihypertensive medica-
tion to decrease cardiovascular complications have been 
established. However, inadequate adherence to anti-
hypertensive therapy or NAM has been linked to the 
development of cardiovascular complications. The NAM 
is described as a widespread problem in an insidious 
chronic condition like HTN [13] and studies have shown 
that populations of African descent with HTN were less 
adherent to medication compared with Caucasians. The 
overall prevalence of medication adherence in this popu-
lation was lower for any definition used [14]. NAM is also 
associated with cardiovascular mortality risk. A cohort 
study conducted in Brazil reported that the risk of mor-
tality from CVD was three times higher in patients dis-
continuing HTN medication compared with those who 
regularly took their medication [15]. Thus, given the 
situation described previously for the DRC, we believe 
that it is essential to identify and gain a better under-
standing of the factors associated with NAM in our set-
tings with the overreaching goal to inform strategies for 
improving patient adherence to medication. Therefore, 
using the WHO framework that describes five dimen-
sions of factors that may affect adherence to therapy and 
the Morisky Medication Scale, a validated self-reported 
medication scale, this study aims to measure non-adher-




From October 2013 to November 2013, a cross-sectional 
study was carried out at Kinshasa Primary Health-care 
(KPHC) network facilities. This network consists of 51 
facilities that allows for follow-up of patients with NCDs 
like hypertension and diabetes, living in Kinshasa [16].
Study population
Inclusion criteria
We included in the study hypertensive patients >18 years 
who have been under antihypertensive drugs for at least 
a month.
Exclusion criteria
Hypertensive pregnant women were excluded.
Sampling
Only 25, out of 51 facilities, scheduled patients’ visits 
during the survey were therefore selected. All patients 
present in the facility and who met the inclusion criteria 
were enrolled. The sample size was computed using the 





 where the p represents the 
proportion of non-adherence to antihypertensive medi-
cation (we assumed that p =  50  % because the propor-
tion of NAM in the DRC is unknown), q (1 − p), z value 
of the standard normal distribution corresponding to a 
significance level of alpha of 0.05 (1.96) and d the pre-
cision degree that we assumed to 5 % too. The minimal 
size computed was 384 patients. A total of 408 patients 
present in the health facilities were selected but only 395 
(96.8  %) were eligible and enrolled. The study protocol 
was approved by the institutional review boards of the 
Kinshasa School of Public Health, Bureau Diocésain des 
Oeuvres Médicales de Kinshasa, and Service Médical 
Armée du Salut and conducted in accordance with the 
Helsinki Declaration II. All study participants provided 
written informed consent.
Data collection and study variables
Patients were surveyed using a structured questionnaire, 
either in French or translated in Lingala, the local lan-
guage. Five surveyors had been trained over 3  days and 
the interview instrument was pretested prior to its use. 
Covariates were defined according to the WHO frame-
work. This framework was used because actually, no 
model of medication adherence for HTN has been pub-
lished. The Health Beliefs Model has been used in several 
studies but it does not include all the dimensions of the 
NAM factors like those described by the WHO frame-
work [17]. The variables collected entailed social and 
economic characteristics of patients (gender, age, mari-
tal status, religious affiliation, education, employment); 
conditions-related variables (duration of HTN, control 
of blood pressure, experience of physical symptoms due 
to HTN, co-morbidity); therapy-related variables (dura-
tion of antihypertensive medication treatment, number 
of pills taken daily, experience of medication side effects, 
use of non-prescribed medication, treatment adherence); 
patients-related variables (knowledge of HTN risk factors 
and complications, knowledge of treatment benefit, per-
ception of hypertension gravity and hypertension-related 
complications gravity, beliefs on BP medications impor-
tance, status acceptation); healthcare team and system-
related variables (patient–provider relationship, patient 
education, perception of treatment cost, geographical 
accessibility, availability of antihypertensive drugs).
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Co-morbidity has been defined in this study as HTN 
associated with diabetes mellitus (DM) or organ damage 
targets (heart disease, strokes, or CKD). Patients were 
interviewed if identified by a health professional as hav-
ing one of these conditions.
Only the blood pressure measured by healthcare 
providers on the day of the survey and recorded in the 
patient medical file was considered. Three hundred 
ninety (390) out of three hundred ninety five (395) had 
the values of blood pressure recorded in their medi-
cal file (98.7  %). Uncontrolled HTN was defined, for 
a patient without co-morbidity, as a patient with a SBP 
≥140 mmHg and a DBP ≥90 mmHg. For a patient with 
co-morbidity, uncontrolled HTN was defined as a patient 
with SBP ≥130 mmHg and for DBP ≥80 mmHg [18].
The self-reported medication adherence was measured 
using the Morisky Scale, which is a validated scale with a 
good internal consistency. Its Cronbach’s alpha has been 
reported to be of 0.90 in studies of inner-city patients 
with hypertension [19, 20]. Patients responded, “yes” or 
“no” to the four questions and have been categorized into 
three groups, namely high, medium and low adherence, 
as summarized in Table 1 [19]. Thereafter, adherence was 
dichotomized in order to facilitate statistical analysis. The 
low and medium adherence was merged and classified 
as non-adherent and patients with high adherence were 
classified as adherent, like previously used by Patel [21].
Statistical analysis
All analyses were performed using Statistical Package for 
Social Sciences (SPSS) version 21.0. (SPSS, Inc., Chicago, 
IL, USA). Descriptive statistics were used to summarize 
the study population characteristics. Continuous vari-
ables were reported using mean with standard deviation. 
Means for age of non-adherent and adherent patients 
were compared using Student’s t test. Categorical vari-
ables were reported as a frequency and percentage and 
groups were compared using χ2 test. The logistic regres-
sion helped to identify independent predictors of non-
adherence. All variables associated with non-adherence 
to antihypertensive medication in the bivariate analysis 
were included in the final model. Odds ratio (OR) with a 
corresponding 95 % confidence interval was reported to 
quantify the strength of association. Significance was set 
at p-value of less than 0.05.
Results
Patients’ socioeconomic and clinical characteristics
Tables  2 and 3 summarize socio-economic and clini-
cal characteristics of the patients. A total of 395 patients 
were assessed. The mean age of participants was 
63.3 ± 9.6 years and nearly 76 % were female; almost half 
were married (45.6 %) and Catholic Christians (48.9 %); 
40.5  % completed at least secondary school and 63.5  % 
were unemployed.
Approximately half of the patients suffered from HTN 
for less than 5  years. The mean systolic blood pressure 
was 148.6  ±  22.1 and 87.8  ±  14.3  mmHg for the dias-
tolic blood pressure. The control of HTN was present in 
15.6 % (95 % CI 12.1–20.0 %) patients. Almost two-thirds 
of the patients (64.6  %) experienced physical symptoms 
due to HTN. Dizziness was the most common physi-
cal symptom reported. Co-morbidities were present in 
53.9 % of participants, of which DM was the most com-
mon (52.4 %).
More than half of the participants had less than 5 years 
of antihypertensive treatment duration. On average, the 
patients took 1.7 ± 1.2 pills daily. Approximately half of 
Table 1 Morisky Scale
Source: Morisky et al. [19]
High adherence, if the sum = 0; medium adherence, if the sum is com-
prised between 1 and 2 and low adherence if the sum is comprised 
between 3 and 4
Have you ever forgotten to take your BP medicine? 0. No 1. Yes
Are you sometimes careless in regard to your medicine? 0. No 1. Yes
Do you skip your medicine when you are feeling well? 0. No 1. Yes
When you feel bad due to the medicine, do you skip it? 0. No 1. Yes
Table 2 Socio-economic characteristics of  hypertensive 
patients, Kinshasa, 2013 (n = 395)
Variables n %
Mean (SD), age 63.3 ± 9.6 years
Female gender 300 75.9
Marital status
 Currently married 180 45.6
 Widowed 178 45.1
 Divorced/separated 24 6.1
 Never married 13 3.3
Religious affiliation
 Catholic Christians 193 48.9
 Protestant Christians 73 18.5
 Pentecostal Christians 61 15.4
 Kimbanguist Christians 24 6.1
 Other religious affiliations 44 11.1
Education
 No formal 82 20.8
 Primary 153 38.7
 Secondary 126 31.9
 Tertiary 34 8.6
Employment
 Unemployed/retired 174 44.0
 Employed 144 36.5
 Housewife 77 19.5
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the patients (55.9 %) experienced medication side effects, 
20.5  % declared taking non-prescribed medications. 
Around one in three patients reported to have forgot-
ten to take blood pressure medicine (31.9 %) and to have 
skipped taking drugs when they felt well (31.4 %). Using 
the Morisky Scale, we found that over half of participants 
(54.2 %) were non-adherent to their medication.
Patients’ knowledge, beliefs and perception
Table  4 summarizes the study of the population knowl-
edge, beliefs and perception about HTN and its treat-
ment. Poor knowledge of the risk factors related to 
lifestyle was observed. Stress/anxiety was the most fre-
quent risk factors mentioned (67.6 %) and stroke was the 
most common complication mentioned (37.2  %). The 
control of blood pressure was the most common men-
tioned benefit of antihypertensive treatment (55.4  %), 
the majority of patients believed in the importance of 
blood pressure medication in controlling BP (86.3  %) 
and accepted their hypertensive status (85.6 %). Also, the 
majority of the patients in this study thought it possible 
to adhere to treatment (92.4 %).
Health team and health system variables
Table  5 summarizes the health team and system vari-
ables and shows that almost all patients declared that 
their relationship with care providers was very good or 
good (94.7 %). More than half of the patients reported 
that their health facility provided hypertensive patients 
with education (65.1  %); 86.3  % declared they payed 
for treatment. Three-quarters of the patients thought 
that the cost of the treatment was inexpensive (73.3 %). 
The majority of the patients reported that antihyper-
tensive drugs were available in the healthcare facility 
when they needed them (87.1 %). The healthcare facili-
ties were for the most part accessible geographically 
(74.2 %).
Table 3 Clinical characteristics of  hypertensive patients, 
Kinshasa, 2013 (n = 395)
Variables n (%)
Duration of hypertension, year
 <5 220 55.7
 ≥5 149 36.7
 Unknown 26 6.6
Duration of antihypertensive treatment, year
 <5 239 60.5
 ≥5 126 31.9
 Unknown 30 7.6
Control of blood pressure, n = 390
 Uncontrolled 329 84.4
 Controlled 61 15.6
Number of pills, n = 395
 Mean (SD) 1.7 (1.2)
Experience of medication side effects 217 54.9
Experience of physical symptoms due to hypertension 255 64.6
Physical symptoms felt, n = 255
 Dizziness 157 61.6
 Tiredness 84 32.9
 Blurred vision 79 30.9
 Headache 60 23.5
 Palpitations 17 6.6
 Additional symptoms 20 7.8
Presence of co-morbidity 213 53.9
Types of co-morbidity
Diabetes 207 52.4
Heart diseases 6 1.5
Taking of non-prescribed medications 81 20.5
Adherence measurement
 Have you ever forgotten to take your BP medicine? 126 31.9
 Are you sometimes careless in regard to your medicine? 84 23.8
 Do you skip your medicine when you are feeling well? 124 31.4
 When you feel bad due to the medicine, do you skip it? 87 22.0
Medication non-adherence 214 54.2
Table 4 Knowledge and  perception of  hypertensive 
patients, Kinshasa, 2013 (n = 395)
Variables n (%)
Risk factors related to HTN mentioned
 Anxiety/stress 267 67.6
 Do not know 61 15.4
 Salt intake/unhealth diet 25 6.3
 Alcohol intake 19 4.8
 Other factors 28 7.1
Hypertension-related complications mentioned
 Stroke 147 37.2
 Death 110 27.8
 Heart diseases 22 5.6
 Diabetes 14 3.5
 Others 18 4.6
Knowledge of treatment benefit
 Control of BP 219 55.4
 Decrease the risk of complications 105 26.6
 Decrease the risk of mortality 46 11.6
 Do not know 24 6.1
 Healing 19 4.8
Beliefs that BP medications are helpful in controlling BP
 Very helpful/helpful 341 86.3
 Somewhat helpful/not helpful 45 11.4
 Do not know 10 2.3
Status acceptation 338 85.6
Self-perception of ability to adhere to treatment 365 92.4
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Predictors of non‑adherence to antihypertensive 
treatment
Table  6 summarizes the predictors of NAM after logis-
tic regression. Poor knowledge about complications of 
hypertension (OR  =  2.4; 95  % CI 1.4–4.4); unavailabil-
ity of antihypertensive drugs in the healthcare facilities 
(OR = 2.8; 95 % CI 1.4–5.5), lack of hypertensive patients 
education in the healthcare facilities (OR  =  1.7; 95  % 
CI 1.1–2.7), prior experience of medication side effects 
(OR = 2.2; 95 % CI 1.4–3.3), uncontrolled blood pressure 
(OR = 2.0; 95 % CI 1.1–3.9) and taking of non-prescribed 
medications (OR = 2.2; 95 % CI 1.2–3.8) were indepen-
dently associated with NAM in this study.
Discussion
This study aimed to measure NAM and to identify its 
predictors. This study found a high prevalence of NAM 
and a poor control of blood pressure. Patients, therapy 
and health system factors were the predictors of NAM.
The prevalence of non-adherence to antihypertensive 
medication was high and consistent with previous find-
ings [14, 22, 23]. However, this prevalence could have 
been underestimated because of two factors: age of the 
patients and level of the facilities surveyed. The mean age 
of patients in this study was 63.3 ± 9.6 years whereas a 
previous study conducted in the DRC reported a mean 
age of 54.3 ± 9.2 years among patients admitted to hos-
pital for HTN-related complications [11]. Previous 
studies reported that, compared with older patients, 
younger patients were more likely to be non-adherent 
[24, 25]. Then, we posed a question on the follow-up of 
the younger hypertensive patients. Probably, younger 
hypertensive patients in Kinshasa are underdiagnosed. 
The Vitaraa Study conducted in Southern Kivu province 
of the DRC reported that more than half of the hyper-
tensive patients were unaware of their status [6]. Given 
that older patients usually have several health concerns, 
the probability of HTN being diagnosed incidentally 
is high. Secondly, this study was carried out in primary 
healthcare facilities that use essential or generic drugs, 
which were inexpensive. The cost of drugs is described as 
a factor of non-adherence; it has been minimized in this 
study. Also, some non-adherent patients may have devel-
oped complications necessitating hospital admission at 
secondary and tertiary facilities. Overall, we believe that 
if this study was carried out at secondary and tertiary lev-
els, the proportion of non-adherence would have been 
higher.
This study also reported a poor control of blood pres-
sure. These findings corroborate previous studies car-
ried out in African populations, where the proportion of 
blood pressure control was very low, less than 10 % [5]. 
This poor control may be explained partly by the pres-
ence of patients with co-morbidity at primary-level care 
facilities. Co-morbidity has been defined in this study as 
HTN associated with diabetes or organ damage targets. 
Hypertensive patients associated with these diseases are 
categorized as high cardiovascular risk and this category 
of patients cannot be followed at the primary-level care 
facilities [18]. The low proportion of blood pressure con-
trol reported in this study could explain the prevalence 
of HTN-related complications reported at secondary and 
tertiary levels care in the DRC.
This study reports poor knowledge about risk factors 
related to HTN. This has also been described by a pre-
vious study carried out in Pakistan [26]. Furthermore, 
stress is the main factor, as corroborated by a study car-
ried out in Zimbabwe where 70.6  % of patients men-
tioned stress as a cause of hypertension [27]. However, 
risk factors related to lifestyle such as obesity, tobacco 
use and excessive alcohol consumption were not often 
mentioned. In this study, stroke has been the most men-
tioned as a complication of HTN in contrast with a study 
conducted in Pakistan, where the heart complication was 
the most mentioned (30.6 %) [24]. This difference may be 
explained by the fact that stroke has been described as a 
major CVD present in the black population [18].
Social and economic factors (education level, sex, age, 
employment) are described by the WHO as the NAM 
factors [14]. In this study none of these factors have been 
associated with NAM. We provided some explanations 
above on age and employment, the latter has not been 
associated with NAM, probably because the majority 
of patients declared that antihypertensive drugs were 
inexpensive.
Hypertension is considered as a condition without 
symptom, the experience of physical symptoms due 
to HTN influences treatment adherence significantly, 
patients who do not feel unwell may be less adherent. In a 
qualitative study carried out in Bandundu (a province of 
Table 5 Health team and system related factors
Perception of patient‑provider relationships n %
Very good/good 374 94.7
Somewhat good/bad 21 5.3
Patient education performed in the healthcare facility 257 65.1
Have paid for treatment 341 86.3
Perception of treatment cost, n = 341
 Very inexpensive/inexpensive 250 73.3
 Very expensive/expensive 24 7.0
 Do not know 67 19.6
Healthcare facility accessible geographically 293 74.2
Availability of antihypertensive medications in the healthcare 
facilities
343 87.0
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the DRC), hypertensive patients reported that they took 
medication only when they experienced perceived symp-
toms of HTN [28]. In this study, no association was found 
between patients experiencing physical symptoms and 
treatment adherence. This result is consistent with a pre-
vious study which did not find this association [29].
Patient education is described as a catalyst for lifestyle 
change and treatment adherence [27]. This association 
with treatment adherence has previously been reported 
[30]. Patient education improves the patient’s under-
standing of diseases, lifestyle change and medication. 
In this study, patients who admitted to benefitting from 
education and who had a good knowledge of hyperten-
sion and its complications respectively were twice more 
likely to be treatment adherent.
Also, this study found that patients who took non-
prescribed medication were twice more likely to be non-
adherent to treatment than other patients. We surmise 
Table 6 Bivariate and multivariate analysis determinants of non-adherence to antihypertensive medication
* p value <0.05
Variables Bivariate analysis Multivariate analysis
Crude OR (95 % CI) P value Adjusted OR (95 % CI) P value
Age 0.782 – –
Gender 0.8 (0.5–1.3) 0.412 – –
Education
 No formal 1.0 (0.5–2.3) 0.921 – –
 Primary 1.9 (0.9–4.2) 0.078 – –
 Secondary 1.5 (0.7–3.3) 0.272 – –
 Tertiary
Occupation
 Unemployed/retired 0.9 (0.6–1.4) 0.832 – –
 Employed
Duration of hypertension, year
 Unknown 0.6 (0.3–1.5) 0.317 – –
 ≥5 1.3 (0.8–1.9) 0.284 – –
 <5
Duration of antihypertensive treatment, year
 Unknown 0.9 (0.4–1.9) 0.897 – –
 ≥5 1.2 (0.8–1.9) 0.342 – –
 <5
Control of blood pressure n = 390
 Uncontrolled 1.8 (1.1–3.2) 0.032* 2.0 (1.1–3.7) 0.018*
Experience of medication side effects 1.9 (1.3–2.9) 0.001* 2.2 (1.4–3.3) 0.001*
Experience of physical symptoms due to hypertension 1.4 (0.9–2.1) 0.122 – –
Presence of Co-morbidity 1.2 (0.8–1.7) 0.465 – –
Taking of non-prescribed medications 1.7 (1.1–2.8) 0.042* 2.2 (1.2–3.8) 0.006*
Poor knowledge of risk factors related to HTN 0.7 (0.5–1.1) 0.140 – –
Poor knowledge of HTN related complications 2.5 (1.4–4.3) 0.001* 2.4 (1.4–4.4) 0.003*
Poor knowledge of treatment benefit 1.5 (0.7–3.1) 0.324 – –
Beliefs that BP medications are helpful in controlling BP 1.3 (0.7–2.3) 0.421 – –
Accept hypertensive status 1.2 (0.7–2.0) 0.589 – –
Perception of HTN gravity 1.1 (0.6–1.8) 0.838 – –
Perception of HTN related complications gravity 1.2 (0.7–2.0) 0.526 – –
Perception of patient-provider relationships 2.0 (0.8–4.9) 0.128 – –
Lack of patient education performed in the healthcare facility 1.9 (1.3–2.9) 0.003* 1.7 (1.1–2.7) 0.023*
Perception of treatment cost 0.9 (0.6–1.6) 0.948 – –
Healthcare facility accessible geographically 0.9 (0.6–1.5) 0.771 – –
Unavailability of antihypertensive medications in the healthcare facilities 2.6 (1.3–5.2) 0.003* 2.8 (1.4–5.5) 0.003*
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that probably these patients use complementary and 
alternative medicine (CAM) which is defined as a “group 
of diverse medical and healthcare systems, practices, and 
products that are not presently considered to be part of 
conventional medicine” [31]. Previous studies reported 
an association between the use of CAM and treatment 
adherence and blood pressure control [32–35]. It is also 
reported that the experience of side effects is among the 
main predictors of CAM use. In this study, patients expe-
riencing side effects were more non-adherent than their 
strong hypothesis of the use of CAM. Unfortunately, the 
use of CAM was not measured in this study, future stud-
ies may be carried out to assess the use of CAM in hyper-
tensive patients in Kinshasa.
Unavailability of antihypertensive medication in health-
care facilities is a barrier to health care and is described 
as a factor of medication non-adherence. Patients who 
reported the availability of antihypertensive medication 
in healthcare facilities were about twice more likely to be 
adherent. These findings are consistent with that previ-
ously reported by Ghozzi in Tunis [36].
We acknowledge some limitations in this study. A 
potential selection bias may have been introduced in 
this study relating to the level of care facilities surveyed. 
Also, information bias was possible—firstly by using the 
self-reported questionnaire for measuring medication 
adherence and secondly by reporting the blood pres-
sure measured by non standardized methods. However, 
these overall findings corroborate those found in previ-
ous studies. We think that the results of this study may be 
generalized to hypertensive patients living in Kinshasa.
Conclusion
This is the first study in the DRC with a large sample to 
measure the antihypertensive non-adherence and to 
identify related predictors. These findings show that all 
predictors identified were modifiable by strengthening 
the capacity of healthcare providers by communication 
with patients. Antihypertensive medication should be 
made available in healthcare facilities.
Abbreviations
BP: blood pressure; CAM: complementary and alternative medicine; CKD: 
chronic kidney disease; CVD: cardiovascular diseases; CVRF: cardiovascular 
risk factors; DM: diabetes mellitus; DRC: Democratic Republic of Congo; HTN: 
hypertension; KPHC: Kinshasa Primary Health-care; NAM: non-adherence to 
antihypertensive medication; NCDs: non communicable diseases; OR: odds 
ratio; SSA: Sub-Saharan Africa; WHO: World Health Organization.
Authors’ contributions
LN, AL and PM designed the research, AL and PM conducted the fieldwork 
and analyzed data; AL, PM and EM wrote the paper; and AM, MM, PK and YC 
revised the manuscript. AL has the primary responsibility for the final content. 
All authors read and approved the final manuscript.
Author details
1 Department of Epidemiology and Bio-statistics, Faculty of Medicine, Kinshasa 
School of Public Health, University of Kinshasa, PO Box 11850, Kinshasa, DR 
Congo. 2 Programme National Multisectoriel de Lutte contre le VIH, Ministère 
de la Santé, Kinshasa, DR Congo. 3 Department of Epidemiology, Bio-statistics 
and Occupational Health, Mc Gill University, Montreal, QC, Canada. 4 Ecole de 
Santé Publique, Université libre de Bruxelles, Brussels, Belgium. 
Acknowledgements
We acknowledge the Bureau Diocésain des Oeuvres médicales de Kinshasa 
(BDOM) and the Bureau Médical de l’Armée du Salut for their approval for 
data collection in their health care facilities. We acknowledge, too, all health 
care providers and patients for their participation. We are thankful to the 
United States Agency for International Development (USAID) for their funding 
for data collection. Also, we are grateful to Future Health Systems (FHS) for 
providing small grants to the Kinshasa School of Public Health through Africa 
Hub, funded by the Department for International Development (DFID) for 
stationery paper. These funding sources are non-commercial.
Compliance with ethical guidelines
Competing interests
The authors declare that they have no competing interests.
Received: 7 May 2015   Accepted: 21 September 2015
References
 1. Kearney MP, Whelton M, Reynolds K, Muntner P, Whelton KP, He J. 
Global burden of hypertension: analysis of worldwide data. Lancet. 
2005;365:217–23.
 2. Dalal S, Beunza JJ, Volmink J, Adebamowo C, Bajunirwe F, Njelekela M, 
et al. Non- communicable diseases in sub-Saharan Africa: what we know 
now. Int J Epidemiol. 2011;40:885–901.
 3. M’Buyamba-Kabangu JR, Fagardr ST, Lijnen P, Amery A. Correlates of 
blood pressure in rural and urban Zaire. J Hypertens. 1987;5:371–5.
 4. Longo MB, Ngoma VD, Nahimana D, Mupepe MD, Mbungu FS, Ekwanzala 
F, Beya C. Screen detection and the WHO stepwise approach to the 
prevalence and risk factors of arterial hypertension in Kinshasa. Eur J 
Cardiovasc Prev Rehabil. 2008;15:503–8.
 5. Lwelunmor J, Airhihenbuwa CO, Cooper R, Tayo B, Plange-Rhule J, 
Adanu R, Ogedegbe G. Prevalence, determinants and systems-thinking 
approaches to optimal hypertension control in West Africa. Glob Health. 
2014;10:42.
 6. Katchunga BP, Mbuyamba KJR, Masumbuka EB, Lemogoum D, 
Kashongwe MZ, Degaute JP, et al. Hypertension in adult Congolese 
population in Southern Kivu: results of the Vitaraa Study. Presse Médicale. 
2011;. doi:10.1016/jlpm2010.10.036.
 7. Connor M, Rheeder P, Bryer A, Meredith M, Beukes M, Dubb A, et al. 
The South African stroke risk in general practice study. S Afr Med J. 
2005;95:334–9.
 8. World Health Organization. Reducing risks, promoting healthy life. In 
the World Health report 2002. Geneva: World Health Organization; 
2002.
 9. Sumaili EK, Krzesinski JM, Cohen EP, Nseka NM. Epidemiologie de la 
maladie rénale chronique en Republique Démocratique du Congo: 
revue des études transversales de Kinshasa, la capitale. Nephrol Ther. 
2010;6(4):232–9.
 10. Sumaili KE, Nseka NM, Makulo JRR, Zinga CV, Longo AL, Mukendi SK 
et al. Statut socioéconomique et protéinurie: résultats de campagne 
de dépistage des maladies des reins 2007 à Kinshasa. Ann Afr Med. 
2009;2(3):170–7.
 11. M’Buyamba KJR, Biswika RT, Thijs L, Tshimanga GM, Ngalula FM, Disashi 
T, et al. In-hospital mortality among black patients admitted for 
hypertension-related disorders in Mbuji Mayi, Congo. Am J Hypertens. 
2009;22:643–8.
Page 8 of 8Lulebo et al. BMC Res Notes  (2015) 8:526 
 12. Matsumura K, Arima H, Tominaga M, Ohtsubo T, Sasaguri T, Fujii K, et al. 
Impact of antihypertensive medication adherence on blood pressure 
control in Hypertension: the COMFORT study. Q J Med. 2013;106:909–14.
 13. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 
2005;353(5):487–97.
 14. Sabate E. Adherence to long-term therapies: evidence for action. Geneva: 
World Health Organization; 2003.
 15. Correa Leite ML, Firmo JOA, Loyola Filho AI, Lima-costa MF. Discontinua-
tion of anti-hypertensive drugs increases 11-year cardiovascular mortality 
risk in community-dwelling elderly (the Bambui Cohort Study of Ageing). 
BMC Public Health. 2014;14:725.
 16. Kapongo YR, Lulebo MA, Mafuta ME, Mutombo BP, Dimbelolo MJC, Bieleli 
IE. Assessment of health service delivery capacities, health providers’ 
knowledge and practices related to type 2 diabetes care in Kinshasa 
primary health care network facilities, Democratic Republic of Congo. 
BMC Health Serv Res. 2015;15:9.
 17. Stretcher V, Rosenstock IM. The Health Belief Model. In: Glanz K, Lewis FM, 
Rimer BK, editors. Health behavior and health education: theory, research 
and practice. San Francisco: Jossey-Bass; 1997.
 18. Lemogoum D, Seedat YK, Mabadeje AF, Mendis S, Bovet P, Onwubere 
B, et al. Recommendations for prevention, diagnosis and management 
of hypertension and cardiovascular risk factors in sub-Saharan Africa. J 
Hypertens. 2003;21:1993–2000.
 19. Morisky DE, Green LW, Levine DM. Concurrent and predictive valid-
ity of a self-reported measure of medication adherence. Med Care. 
1986;24:67–74.
 20. Shea S, Misera D, Ehrlich MA. Correlates of non adherence to hyperten-
sion treatment in an inner-city minority population. Am J Public Health. 
1992;82:1607–12.
 21. Patel RP, Taylor SD. Factors affecting medication adherence in hyperten-
sive patient. Ann Pharmacother. 2002;36:40–5.
 22. Lewis LM, Schoenthaler AM, Ogedegbe G. Patients factors, but not 
provider and health care system factors, predict medication adherence in 
hypertensive black men. J Clin Hypertens. 2012;14:250–5.
 23. Queiroz Godoy ACD, Velludo EV. Factors that interfere the medication 
compliance in hypertensive patients. Einstein. 2013;11(3):331–7.
 24. Lee KYG, Wang HXH, Liu QLK, Cheung Y, Morisky ED, Wong CSM. 
Determinants of medication adherence to antihypertensive medication 
among a Chinese population using Morisky Adherence Scale. PLoS One. 
2013;8(4):2775. doi:10.1371/journal.pone.0062775.
 25. Burnier M. Medication adherence and persistence as the cornerstone of 
effective antihypertensive therapy. Am J Hypertens. 2006;19:1190–6.
 26. Almas A, Siraj GS, Lalani S, Aziz SZ, Hameed KA. Good knowledge about 
hypertension is linked to better control of hypertension; a multicentre 
cross-sectional study in Karachi, Pakistan. BMC Res Notes. 2012;5:579.
 27. Mungati M, Manangazira P, Takundwa L, Gombe NT, Rusakaniko S, Tshi-
manga M. Factors affecting diagnostics and management of hyperten-
sion in Mazowe District of Mashonaland Central Province in Zimbabwe: 
2012. BMC Cardiovasc Disord. 2014;14:102.
 28. Fina LJP, Mabuza L, Malete N, Maduna P, Ndimande VJ. Reasons for 
non-compliance among patients with hypertension at Vanga Hospital, 
Bandundu province, Democratic Republic of Congo: a qualitative study. 
Afr J Prim Health Care Fam Med. 2009;. doi:10.4102/phcfm.Vlil.68.
 29. Okken VS, Niemeijer MG, Dijkstra A, Baars MW, Said S, Hoogenberg K, et al. 
The effect of physical, social and psychological factors on drug compli-
ance in patients with mild hypertension. Neth Heart J. 2008;16:197–200.
 30. Saounatsou M, Patsi O, Fasoi G, Stylianou M. The influence of the hyper-
tensive patient’s education in compliance with their medication. Public 
Health Nurs. 2001;18(6):436–42.
 31. NCCAM (National Center for Complementary and Alternative Medicine). 
2015. http://nccam.nih.gov/health/whatiscam/. Accessed 13 Mar 2015
 32. Kretchy AI, Owusu-Daaku TF, Danquah S. Locus of control and antihyper-
tensive medication adherence in Ghana. Pan Afr Med J. 2014;17(Supp 
1):13.
 33. Okoro RN, Ngong CK. Assessment of patient’s antihypertensive medica-
tion adherence level in non-comorbid hypertension in a tertiary hospital 
in Nigeria. Int J Pharm Biomed Sci. 2012;3(2):47–54.
 34. Siew-Mooi C, Vasudevan R, Zacharia Z, Paimin F. Frequency of comple-
mentary and alternative medicine usage among Malaysian hypertensive 
subjects. Life Sci J. 2013;10(4):2526–31.
 35. Kretchy AI, Owusu-Daaku F, Danquah F. Patterns and determinants of 
the use of complementary and alternative medicine: a cross-sectional 
study of hypertensive patients in Ghana. BMC Complement Altern Med. 
2014;14:44.
 36. Ghozzi H, Kassis M, Hakim A, Sahnoun Z, Abderrhmen A, Abbes R, et al. 
Observance médicamenteuse chez un échantillon d’hypertendus dans la 
région de Sfax (Tunisie). Ann Cardiol Angeiol. 2010;59(3):131–7.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
